Exhaled breath analysis using eNose technology to detect acute cellular rejection and chronic lung allograft rejection in patients after lung transplantation

In patients with end-stage lung disease, lung transplantation could be a lifesaving treatment option. However, patients after lung transplantation encounter higher health resource utilization, more transplant-related complications, and higher mortality rates compared to recipients of other solid organs. Early detection of complications such as acute cellular rejection (ACR) and chronic lung allograft dysfunction (CLAD) could prolong survival. Exhaled breath analysis using electronic nose (eNose) technology could provide a fast and non-invasive tool for the diagnosis of ACR and CLAD in patients after lung transplantation. In the Erasmus Medical Center we will ask lung transplant recipients to participate in this observational study.

The aim of this pilot study is to assess the feasibility and reliability of exhaled breath analysis using eNose technology for diagnosing ACR and/or CLAD in lung transplant recipients. To achieve this aim we will:

- Evaluate whether the breathprint of stable lung transplant recipients differ from lung transplant recipients with CLAD
- Evaluate whether the breathprint of stable lung transplant recipients differ from lung transplant recipients with ACR

The eNose will be able to discriminate stable patients from patients with CLAD and ACR, and between ACR and CLAD

eNose measurements will be performed before or after routine outpatient clinic visits in stable patients and during each additional outpatient clinic visit

Not applicable